**Lenti-shRNA Core Facility**

**shRNA Bacterial Glycerol Stock Ordering Form**

|  |  |
| --- | --- |
| Order Date |  |
| P.I. Name |  |
| CB#, Building, Room # |  |
| Contact Phone # |  |
| Chart field  (Fd code-Source-Dept ID-Proj ID) |  |
| User's Name |  |
| User's Email |  |
| Billing Contact’s Name |  |
| Billing Contact’s Email |  |

**BIOSAFETY CONCERNS**

* Vector particles should be handled in a BSL-2 facility.
* Use all necessary protective gear.
* Keep sharps out of the tissue-culture hood.
* Follow your lab’s biosafety plan.
* Be aware of the fact that VSV-G pseudotyped HIV-1 vector particles can transduce human cells *in vivo.*
* Theoretically, exposure to HIV-1 particles can result in seroconversion

**Please note that it is the investigator’s responsibility to get UNC Institutional Biosafety Committee approval to use the required shRNA clones.**

I acknowledge that I have reviewed the above safety information and agree to adhere to the UNC Biosafety Committee’s requirements.

|  |  |
| --- | --- |
| Pick Up Date |  |
| Pick up Person's Signature |  |
| Pick up Person’s Name |  |

If there are more than 5 shRNA clones for one target gene, we consider them as two sets; therefore, the charge will be doubled

|  |  |  |  |
| --- | --- | --- | --- |
| **Accession # of Target Gene** | **Set of shRNA Clones (Check here if you need the whole set of shRNA clones)** | **Oligo ID # of Individual shRNA Clone (for example: TRCN00000041054)** | **Comment** |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |
|  |  |  |  |
|  |
|  |
|  |
|  |